Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of acquisition, earning more than $7.3 billion in revenue from 2017 to 2022, according to a report issued by the Federal Trade Commission (FTC) on Tuesday.
FTC: Big 3 PBMs generated $7.3B from specialty generic drug markups
CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal Trade Commission (FTC) uncovered in its second interim staff report rele | The FTC released its second interim staff report Tuesday during Chair Lina Khan's final open commission meeting,
The Baltimore City Board of School Commissioners is suing Eli Lilly and Co., UnitedHealth Group, CVS and several other drug ...
An Alabama lawmaker believes prescription care management should be a legislative priority during the upcoming session.
Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...
The Federal Trade Commission on Tuesday released an interim report saying that powerful drug middlemen marked up drugs for ...
The Massachusetts Democrat is working with a Missouri Republican, and House members from each party, to press the FTC to ...
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...
President Donald Trump's effect on bank capital rules, crypto policy, antitrust scrutiny, and drug pricing are among key 2025 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback